Ajovy (fremanezumab) is a preventive migraine treatment that works by blocking a protein called CGRP, one of the key chemical messengers involved in migraine attacks. It’s given as an injection under the skin, either once a month or once every three months, and it starts reducing migraine days within the first month of treatment.
How Ajovy Blocks Migraine Signals
During a migraine, nerve fibers around the brain release a protein called CGRP (calcitonin gene-related peptide). This protein binds to receptors on nearby cells, triggering a cascade of events: blood vessels dilate, surrounding tissue becomes inflamed, and pain signals intensify. People with frequent migraines tend to have elevated CGRP levels, and infusing CGRP into migraine-prone individuals can trigger an attack. This makes CGRP a central player in the migraine process.
Ajovy is a monoclonal antibody, a lab-engineered protein designed to seek out and latch onto CGRP before it can do its job. Specifically, it binds to the exact region of the CGRP molecule that would normally attach to its receptor. With that binding site blocked, CGRP can no longer dock with its receptor and kick off the signaling chain that leads to pain, inflammation, and the other symptoms of a migraine. Ajovy neutralizes both major forms of CGRP (alpha and beta), effectively lowering the amount of active CGRP circulating in your system.
Because Ajovy targets the CGRP molecule itself rather than the receptor it binds to, it works like a sponge, soaking up CGRP in the bloodstream and around sensory nerves before it ever reaches its destination. This approach interrupts the cycle at its source and is why Ajovy is used preventively rather than as an acute treatment once a migraine has already started.
Dosing Options: Monthly or Quarterly
Ajovy offers two dosing schedules, which is somewhat unusual for migraine prevention medications. You can take 225 mg once a month as a single injection, or 675 mg once every three months (administered as three consecutive 225 mg injections in one sitting). Both schedules produce similar results in clinical trials, so the choice comes down to personal preference. Some people prefer the convenience of fewer injection days per year, while others would rather give themselves one shot at a time.
Ajovy has a long half-life of about 31 days, meaning it takes roughly a month for the concentration in your body to drop by half. This slow clearance is what makes quarterly dosing possible. After the three-injection quarterly dose, enough of the drug stays active in your bloodstream to maintain its protective effect for the full three months.
How Quickly It Works
In clinical trials, Ajovy showed a reduction in migraine days starting in the first month of treatment. For the quarterly dosing schedule, the benefit was relatively consistent across all three months of the dosing cycle. In chronic migraine patients, the treatment response held steady at around 4.3 fewer headache days per month compared to baseline. In episodic migraine patients, the effect actually improved slightly over the 12-week period, going from about 3 fewer migraine days in the first month to 3.7 fewer by the third month.
This early onset is a notable advantage. Many older preventive migraine medications, like certain blood pressure drugs or antidepressants repurposed for migraine, can take two to three months before their full benefit becomes apparent.
How Much It Reduces Migraine Days
Ajovy’s effectiveness has been measured against placebo in large clinical trials involving both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month). Compared to placebo, Ajovy reduced monthly migraine days by 1.3 to 1.5 days for episodic migraines and 1.7 to 2.1 days for chronic migraines. These are averages across large groups, so individual responses vary. Some people experience dramatic reductions, while others see more modest improvement.
To put those numbers in context, a reduction of 2 days per month for someone with chronic migraine means roughly 24 fewer migraine days per year. For people who respond particularly well, the real-world reduction can be significantly larger than the trial averages suggest, because clinical trials include everyone, even non-responders, which pulls the average down.
Where Ajovy Fits in Migraine Treatment
The American Headache Society now considers CGRP-targeting therapies like Ajovy a first-line option for migraine prevention. This is a meaningful shift. Previously, guidelines often required patients to try and fail older, less targeted medications (like certain antidepressants, anti-seizure drugs, or blood pressure medications) before being approved for a CGRP therapy. The updated position, based on more than 150 clinical and real-world studies, encourages clinicians to consider these treatments early rather than as a last resort. As the AHS clarified, these aren’t necessarily “the” first-line therapy, but they should be “a” first-line option, meaning patients shouldn’t have to cycle through other drugs first.
Side Effects and Injection Experience
The most common side effect of Ajovy is a reaction at the injection site. In clinical trials, about 43 to 45% of people receiving Ajovy reported some form of injection site reaction, compared to 38% of those receiving placebo injections. These reactions include pain, redness, and hardness at the injection site, and they’re generally mild and short-lived. The relatively small gap between the Ajovy and placebo groups (about 5 to 7 percentage points) suggests that much of the discomfort comes from the injection itself rather than the medication.
Serious side effects are uncommon. Ajovy doesn’t interact with the liver enzymes that process most other medications, so drug interactions are minimal. Because it targets a very specific protein rather than broadly affecting brain chemistry, it avoids many of the systemic side effects associated with older preventive migraine treatments, like weight gain, drowsiness, or cognitive fog.
Storage and Handling
Ajovy comes as a prefilled syringe or autoinjector and needs to be stored in the refrigerator between 2°C and 8°C (about 36°F to 46°F). If you need to travel or don’t have immediate access to a fridge, it can stay at room temperature (up to 30°C or 86°F) for a maximum of 7 days. After that window, it must be discarded. Once you’ve taken it out of the refrigerator, don’t put it back. Many people let the injection warm to room temperature for about 30 minutes before injecting, which can make the shot more comfortable.